Premium
Toll‐like receptors in rheumatic diseases: Are we paying a high price for our defense against bugs?
Author(s) -
Santegoets K.C.M.,
van Bon L.,
van den Berg W.B.,
Wenink M.H.,
Radstake T.R.D.J.
Publication year - 2011
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/j.febslet.2011.04.028
Subject(s) - immunology , rheumatoid arthritis , medicine , psoriatic arthritis , receptor , gout , inflammation , pathogenesis , immune system , toll like receptor , toll , psoriasis , innate immune system
In the last decade Toll‐like receptor (TLR) research has led to new insights in the pathogenesis of many rheumatic diseases. In autoimmune diseases like systemic lupus erythematosus, rheumatoid arthritis and systemic sclerosis TLR signaling is likely to be involved in tolerance breakthrough and chronic inflammation via combined Fc gamma receptors and TLR recognition of immune complexes. Furthermore, inflammatory diseases like psoriatic arthritis and gout also show more and more evidence for TLR involvement. In this review we will discuss the involvement of TLR signaling in several rheumatic diseases and stress their similarities and differences based on recent findings.